|
1
|
te Poele EM, Tissing WJ, Kamps WA and de
Bont ES: Risk assessment in fever and neutropenia in children with
cancer: What did we learn? Crit Rev Oncol Hematol. 72:45–55. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ozer H, Armitage JO, Bennett CL, Crawford
J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC,
et al: 2000 update of recommendations for the use of hematopoietic
colony-stimulating factors: Evidence-based, clinical practice
guidelines. American Society of Clinical Oncology Growth Factors
Expert Panel. J Clin Oncol. 18:3558–3585. 2000.PubMed/NCBI
|
|
3
|
Crawford J, Dale DC and Lyman GH:
Chemotherapy-induced neutropenia: Risks, consequences and new
direction for its management. Cancer. 100:228–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weycker D, Barron R, Kartashov A, Legg J
and Lyman GH: Incidence, treatment and consequences of
chemotherapy-induced febrile neutropenia in the inpatient and
outpatient settings. J Oncol Pharm Pract. 20:190–198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynn JJ, Chen KF, Weng YM and Chiu TF:
Risk factors associated with complications in patients with
chemotherapy-induced febrile neutropenia in emergency department.
Hematol Oncol. 31:189–196. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dulisse B, Li X, Gayle JA, Barron RL,
Ernst FR, Rothman KJ, Legg JC and Kaye JA: A retrospective study of
the clinical and economic burden during hospitalizations among
cancer patients with febrile neutropenia. J Med Econ. 16:720–735.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh
MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA and Wingard
JR: Clinical practice guideline for the use of antimicrobial agents
in neutropenic patients with cancer: 2010 update by the Infectious
Diseases Society of America. Clin Infect Dis. 52:e56–e93. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boada Burutaran M, Guadagna1 R, Grille S,
Stevenazzi M, Guillermo C and Diaz L: Results of high-risk
neutropenia therapy of hematology-oncology patients in a university
hospital in Uruguay. Rev Bras Hematol Hemoter. 37:28–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Villela L and Bolaños-Meade J: Acute
myeloid leukaemia: Optimal management and recent developments.
Drugs. 71:1537–1550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cooper KL, Madan J, Whyte S, Stevenson MD
and Akehurst RL: Granulocyte colony-stimulating factors for febrile
neutropenia prophylaxis following chemotherapy: Systematic review
and meta-analysis. BMC Cancer. 11:4042011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith TJ, Khatcheressian J, Lyman GH, Ozer
H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J,
Cross SJ, et al: 2006 update of recommendations for the use of
white blood cell growth factors: An evidence-based clinical
practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aapro MS, Cameron DA, Pettengell R,
Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen
VC, Walewski J, et al: EORTC guidelines for the use of
granulocyte-colony stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphomas and solid tumors. Eur J Cancer. 42:2433–2453. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lyman GH, Kuderer N, Greene J and Balducci
L: The economics of febrile neutropenia: Implications for the use
of colony-stimulating factors. Eur J Cancer. 34:1857–1864. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hosmer W, Malin J and Wong M: Development
and validation of a prediction model for the risk of developing
febrile neutropenia in the first cycle of chemotherapy among
elderly patients with breast, lung, colorectal and prostate cancer.
Support Care Cancer. 19:333–341. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita M, Tokunaga S, Ikegame S, Harada E,
Matsumoto T, Uchino J, Watanabe K and Nakanishi Y: Identifying risk
factors for refractory febrile neutropenia in patients with lung
cancer. J Infect Chemother. 18:53–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bodey GP and Rolston KV: Management of
fever in neutropenic patients. J Infect Chemother. 7:1–9. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hughes WT, Armstrong D, Bodey GP, Bow EJ,
Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL and
Young LS: 2002 guidelines for the use of antimicrobial agents in
neutropenic patients with cancer. Clin Infect Dis. 34:730–751.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yasufuku T, Shigemura T, Tanaka K, Arakawa
S, Miyake H and Fujisawa M: Risk factors for refractory febrile
neutropenia in urological chemotherapy. J Infect Chemo. 19:211–216.
2013. View Article : Google Scholar
|
|
19
|
Balducci L and Extermann M: Management of
cancer in the older person: A practical approach. Oncologist.
5:224–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aslani A, Smith RC, Allen BJ, Pavlakis N
and Levi JA: The predictive value of body protein for
chemotherapy-induced toxicity. Cancer. 88:796–803. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Christopher R and Friese RN: Chemotherapy
induced neutropenia: Important new data to guide nursing assessment
and management. Adv Stud Nurs. 4:21–25. 2006.
|
|
22
|
Buffler PA, Kwan ML, Reynods P and Urayama
KY: Environmental and genetic risk factors for childhood leukemia:
Appraising the evidence. Cancer Invest. 23:60–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lyman GH, Kuderer NM and Balducci L:
Cost-benefit analysis of granulocyte colony-stimulating factor in
the management of elderly cancer patients. Curr Opin Hematol.
9:207–214. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gomez H, Hidalgo M, Casanova L, Colomer R,
Pen DL, Otero J, Rodríguez W, Carracedo C, Cortés-Funes H and
Vallejos C: Risk factors for treatment-related death in elderly
patients with aggressive non-Hodgkin's lymphoma: Results of a
multivariate analysis. J Clin Oncol. 16:2065–2069. 1998.PubMed/NCBI
|
|
25
|
Caggiano V, Stolshek BS, Delgado DJ and
Carter WB: First and all cycle febrile neutropenia hospitalizations
(FNH) and costs in intermediate grade non-Hodgkin's lymphoma (IGL)
patients on standard-dose CHOP therapy. Blood. 98:431a(abstract
1810). 2001.
|
|
26
|
Meza L, Baselga J, Holmes FA, Liang B and
Breddy J: Incidence of febrile neutropenia (FN) is directly related
to duration of severe neutropenia (DSN) after myelosuppressive
chemotherapy. Proc Am Soc Clin Oncol. 21:255b(abstract 2840).
2002.
|
|
27
|
Wilson-Royalty M, Lawless G, Palmer C and
Brown R: Predictors for chemotherapy-related severe or febrile
neutropenia: A review of the clinical literature. J Oncol Pharm
Pract. 7:141–147. 2002. View Article : Google Scholar
|
|
28
|
Ghalaut PS, Sen R and Dixit G: Role of
granulocyte colony stimulating factor (G-CSF) in chemotherapy
induced neutropenia. J Assoc physician India. 56:942–944. 2008.
|
|
29
|
Heil G, Hoelzer D, Sanz MA, Lechner K, Liu
Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, et al: A
randomized, double blind, placebo-controlled phase III study of
filgrastim in remission induction and consideration therapy for
adults with de novo acute myeloid leukemia. The International Acute
Myeloid Leukemia Study Group. Blood. 90:4710–4718. 1997.PubMed/NCBI
|
|
30
|
Larson RA, Dodge RK, Linker CA, Stone RM,
Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD,
et al: A randomized controlled trial of filgrastim during remission
induction and consolidation chemotherapy for adults with acute
lymphoblastic leukemia. CALGB study 9111. Blood. 92:1556–1564.
1998.PubMed/NCBI
|
|
31
|
Mahmud S, Ghafoor T and Badsha S:
Bacterial infections in pediatric patients with chemotherapy
induced neutropenia. JPMA. 54:2372004.
|
|
32
|
Anunnatsiri S, Chansung K, Chetchotisakd P
and Sirijerachai C: Febrile neutropenia: A retrospective study in
Srinagarind Hospital. J infect Dis Antimicrob agents. 15:115–122.
1998.
|
|
33
|
Keefe DM, Schubert MM, Elting LS, Sonis
ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB,
Hutchins RD and Peterson DE: Updated clinical practice guidelines
for the prevention and treatment of mucositis. Cancer. 109:820–831.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bodey GP, Buckley M, Sathe YS and
Freireich EJ: Quantitative relationships between circulating
leukocytes and infection in patients with acute leukemia. Ann
Intern Med. 64:328–340. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Repetto L: Incidence and clinical impact
of chemotherapy induced myelotoxicity in cancer patients: An
observational retrospective survey. Crit Rev Oncol Hematol.
72:170–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ozer H: The timing of chemotherapy-induced
neutropenia and its clinical and economic impact. Oncology
(Williston Park). 20:11–15. 2006.PubMed/NCBI
|
|
37
|
Citron ML, Berry DA, Cirrincione CT, Hudis
C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R,
Ingle JN, et al: Randomized trial of dose-dense versus
conventionally scheduled and sequential versus concurrent
combination chemotherapy as postoperative adjuvant treatment of
node-positive primary breast cancer: First report of Intergroup
Trial C9741/cancer and Leukemia Group B Trial 9741. J Clin Oncol.
21:1431–1439. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Caggiano V, Weiss R, Rickert TS and
Linde-Zwirble WT: Incidence, cost and mortality of neutropenia
hospitalization associated with chemotherapy. Cancer.
103:1916–1924. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kuderer N, Cosler LE, Crawford J, Dale DC
and Lyman GH: Cost and mortality associated with febrile
neutropenia in adult cancer patients. Proc Am Soc Clin Oncol.
21:250a(abstract 998). 2002.
|
|
40
|
Gandhi SK, Arguelles L and Boyer JG:
Economic impact of neutropenia and febrile neutropenia in breast
cancer: Estimates from two national databases. Pharmacotherapy.
21:684–690. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weycker D, Malin J, Edelsberg J, Glass A,
Gokhale M and Oster G: Cost of neutropenic complications of
chemotherapy. Ann Oncol. 19:454–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
